PolyPeptide Group
biotech · pharmaceutical manufacturing · CDMO
Samsung Biologics to acquire Swiss PolyPeptide Group for $1.8B
July 20, 2026
The deal buys a foothold in GLP-1 peptide manufacturing, the fastest-growing niche in a CDMO market Samsung already dominates in antibodies.
Lead Investors
Samsung Biologics
Read the Full Story in Velocity
Get curated startup and tech news with new stories published daily, company insights, and real-time alerts.